These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33069858)

  • 21. The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort.
    Patel S; Shin GY; Wijewardana I; Vitharana SR; Cormack I; Pakianathan M; Harrison TS; Bicanic T
    J Infect; 2013 Jan; 66(1):75-9. PubMed ID: 23046967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.
    Ford N; Shubber Z; Jarvis JN; Chiller T; Greene G; Migone C; Vitoria M; Doherty M; Meintjes G
    Clin Infect Dis; 2018 Mar; 66(suppl_2):S152-S159. PubMed ID: 29514236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.
    Drain PK; Kleene JM; Coleman SM; Losina E; Katz JN; Giddy J; Ross D; Freedberg KA; Bassett IV
    HIV Med; 2015 Nov; 16(10):640-4. PubMed ID: 25958770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for cryptococcal antigen in asymptomatic people with HIV: urgent need in Eastern India.
    Chakravarty J; Reddy S; Gupta MK; Tilak R; Diwaker C; Sundar S
    AIDS; 2023 Dec; 37(15):2359-2363. PubMed ID: 37650766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
    Cassim N; Schnippel K; Coetzee LM; Glencross DK
    PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
    Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
    Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment.
    Sawadogo S; Makumbi B; Purfield A; Ndjavera C; Mutandi G; Maher A; Kaindjee-Tjituka F; Kaplan JE; Park BJ; Lowrance DW
    PLoS One; 2016; 11(10):e0161830. PubMed ID: 27760140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.
    Frola C; Guelfand L; Blugerman G; Szyld E; Kaufman S; Cahn P; Sued O; Pérez H
    PLoS One; 2017; 12(6):e0178721. PubMed ID: 28617817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.
    Pett SL; Spyer M; Haddow LJ; Nhema R; Benjamin LA; Najjuka G; Bilima S; Daud I; Musoro G; Kitabalwa J; Selemani G; Kandie S; Cornelius KM; Katemba C; Berkley JA; Hassan AS; Kityo C; Hakim J; Heyderman RS; Gibb DM; Walker AS;
    AIDS; 2021 Mar; 35(4):585-594. PubMed ID: 33306556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran.
    Bandalizadeh Z; Shokohi T; Moosazadeh M; Keikha N; Seyedpor H; Rabie Rudsari M; Babamahmoudi F; Ghasemian R; Mardani M; Javanian M; Soleimanpour S; Sefidgar AA; Shokri M; Gouya MM; Seyedmousavi S
    Curr Microbiol; 2020 Aug; 77(8):1667-1672. PubMed ID: 32296917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymptomatic Cryptococcal Antigenemia in People Living with HIV (PLHIV) with Severe Immunosuppression: Is Routine CrAg Screening Indicated in India?
    Anuradha S; H AN; Dewan R; Kaur R; Rajeshwari K
    J Assoc Physicians India; 2017 Apr; 65(4):14-17. PubMed ID: 28527158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
    Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.
    Vidal JE; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2015 Sep; 57 Suppl 19(Suppl 19):38-45. PubMed ID: 26465368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure.
    Mpoza E; Rajasingham R; Tugume L; Rhein J; Nabaggala MS; Ssewanyana I; Nyegenye W; Kushemererwa GE; Mulema V; Kalamya J; Kiyaga C; Kabanda J; Ssali M; Boulware DR; Meya DB
    Clin Infect Dis; 2020 Oct; 71(7):1726-1731. PubMed ID: 31679007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis.
    Temfack E; Bigna JJ; Luma HN; Spijker R; Meintjes G; Jarvis JN; Dromer F; Harrison T; Cohen JF; Lortholary O
    Clin Infect Dis; 2019 Feb; 68(4):688-698. PubMed ID: 30020446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.